Hot Investor Mandate: Investment Firm in the UK Invests in Diagnostics & Digital Health Companies Across the Globe, Usually in Pre-Seed to Series A Rounds 

14 Dec

A venture capital firm headquartered in London invests in early-stage global health-tech companies from Pre-Seed to Series A rounds with flexible check sizes. RYSE has partnerships with key accelerators, global pharmaceuticals, and government organizations.  
 
The firm invests in digital health, diagnostics, and data applications such as CRMs and databases. The firm does not invest in therapeutics. The firm is generally indication-agnostic but has a preference in oncology. 
 
The firm will act as a lead and co-investor and typically takes board or observer seats. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Leave a comment